Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: Current status and perspectives

Critical Reviews in Oncology/Hematology

Volumn 73, Issue 3, 2010, Pages 202-212

  Lamuraglia, Michele ^a,b,c,d   Bridal, S Lori ^a,b   Santin, Mathieu ^a,b   Izzi, Gianni ^c   Rixe, Olivier ^e   Paradiso, Angelo ^c   Lucidarme, Olivier ^a,b,d  

^a SORBONNE UNIVERSITÉ   (France)

^b CNRS   (France)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Contrast agent; Contrast enhanced ultrasound (CEUS); Monitoring anti angiogenesis treatment

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; \BAY 57 9352; ADO 150; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BAY 57 9352; BEVACIZUMAB; BISPHERE; BR; BR 1; BR 14; BY 963; CEDIRANIB; CONTRAST MEDIUM; ECHOVIST; FLUORODEOXYGLUCOSE; GADOLINIUM; GP 547632; IMATINIB; INTERFERON; MONOCLONAL ANTIBODY DC101; PAZOPANIB; PB 127; PERFLEXANE; PERFLUBUTANE; PERFLUTREN; PESDA; SHU 508; SONOVUE; SORAFENIB; SUNITINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG APPROVAL; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; KIDNEY CARCINOMA; LIMB SARCOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MONITORING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION EXPOSURE; REVIEW; SARCOMA; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; ULTRASOUND; ULTRAVIOLET RADIATION; VITAMIN BLOOD LEVEL;

ANGIOGENESIS INHIBITORS; ANIMALS; CONTRAST MEDIA; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ULTRASONOGRAPHY;

EID: 74649084273     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.06.001     Document Type: Review

References (49)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 21 (1971) 1182-1186
2. Lewis W.H. The vascular pattern of tumours. Bull Johns Hopkins Hosp 41 (1927) 156
3. Algire G.H., Chalkley H.W., Legellais F.Y., and Park H.D. Vascular reactions of normal and malignant tissue in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transpants. J Natl Cancer Inst 6 (1945) 73-85
4. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 5706 (2005) 58-62
5. Ferrara N., and vis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 1 (1997) 4-25
6. Shibuya M., and Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312 5 (2006) 549-560
7. Ferrara N., and Keyt B. Vascular endothelial growth factor: basic biology and clinical implications. EXS 79 (1997) 209-232
8. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res 48 10 (1988) 2641-2658
9. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
10. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 2 (2009) 228-247
11. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., and Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60 5 (2000) 1388-1393
12. Padhani A.R., and Husband J.E. Commentary. Are current tumour response criteria relevant for the 21st century?. Br J Radiol 73 874 (2000) 1031-1033
13. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 5 Suppl. 1 (2000) 20-27
14. Ruoslahti E. Antiangiogenics meet nanotechnology. Cancer Cell 2 2 (2002) 97-98
15. Sun S., and Schiller J.H. Angiogenesis inhibitors in the treatment of lung cancer. Crit Rev Oncol Hematol 62 2 (2007) 93-104
16. De Giorgi U., Aliberti C., Benea G., Conti M., and Marangolo M. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 11 17 (2005) 6171-6176
17. Lamuraglia M., Escudier B., Chami L., et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 42 15 (2006) 2472-2479
18. McDonald D.M., and Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat Med 9 6 (2003) 713-725
19. Anderson H., Price P., Blomley M., Leach M.O., and Workman P. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer 85 8 (2001) 1085-1093
20. Padhani A.R., and Neeman M. Challenges for imaging angiogenesis. Br J Radiol 74 886 (2001) 886-890
21. Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med 40 10 (1999) 1706-1715
22. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10 3 (1999) 223-232
23. Brix G., Bahner M.L., Hoffmann U., Horvath A., and Schreiber W. Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT-initial experience. Radiology 210 1 (1999) 269-276
24. Miles K.A., Leggett D.A., and Bennett G.A. CT derived Patlak images of the human kidney. Br J Radiol 72 854 (1999) 153-158
25. Nabavi D.G., Cenic A., Henderson S., Gelb A.W., and Lee T.Y. Perfusion mapping using computed tomography allows accurate prediction of cerebral infarction in experimental brain ischemia. Stroke 32 1 (2001) 175-183
26. Lassau N., Lamuraglia M., Chami L., et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 187 5 (2006) 1267-1273
27. Rouffiac V., Bouquet C., Lassau N., et al. Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol 39 6 (2004) 350-356
28. Lassau N., Lamuraglia M., Leclere J., and Rouffiac V. Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents. J Radiol 85 5 Pt 2 (2004) 704-712
29. Lassau N., Lamuraglia M., Vanel D., et al. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol 16 7 (2005) 1054-1060
30. Hochedez P., Lassau N., Bonvalot S., Bidault S., Leclere J., and Avril M.F. Treatment of local recurrent melanomas by isolated limb perfusion: value of Doppler ultrasonography. J Radiol 84 5 (2003) 597-603
31. Wei K., Jayaweera A.R., Firoozan S., Linka A., Skyba D.M., and Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 97 5 (1998) 473-483
32. Eyding J., Wilkening W., Reckhardt M., et al. Contrast burst depletion imaging (CODIM): a new imaging procedure and analysis method for semiquantitative ultrasonic perfusion imaging. Stroke 34 1 (2003) 77-83
33. Lucidarme O., Kono Y., Corbeil J., Choi S.H., and Mattrey R.F. Validation of ultrasound contrast destruction imaging for flow quantification. Ultrasound Med Biol 29 12 (2003) 1697-1704
34. Krix M., Kiessling F., Farhan N., Schmidt K., Hoffend J., and Delorme S. A multivessel model describing replenishment kinetics of ultrasound contrast agent for quantification of tissue perfusion. Ultrasound Med Biol 29 10 (2003) 1421-1430
35. Arditi M., Frinking P.J., Zhou X., and Rognin N.G. A new formalism for the quantification of tissue perfusion by the destruction-replenishment method in contrast ultrasound imaging. IEEE Trans Ultrason Ferroelectr Freq Control 53 6 (2006) 1118-1129
36. Broumas A.R., Pollard R.E., Bloch S.H., Wisner E.R., Griffey S., and Ferrara K.W. Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow. Invest Radiol 40 3 (2005) 134-147
37. Niermann K.J., Fleischer A.C., Huamani J., et al. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 26 6 (2007) 749-756
38. Pollard R.E., Broumas A.R., Wisner E.R., Vekich S.V., and Ferrara K.W. Quantitative contrast enhanced ultrasound and CT assessment of tumor response to antiangiogenic therapy in rats. Ultrasound Med Biol 33 2 (2007) 235-245
39. Lindner J.R., Dayton P.A., Coggins M.P., et al. Noninvasive imaging of inflammation by ultrasound detection of phagocytosed microbubbles. Circulation 102 5 (2000) 531-538
40. Willmann J.K., Paulmurugan R., Chen K., et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 246 2 (2008) 508-518
41. Korpanty G., Carbon J.G., Grayburn P.A., Fleming J.B., and Brekken R.A. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 13 1 (2007) 323-330
42. Laking G.R., West C., Buckley D.L., Matthews J., and Price P.M. Imaging vascular physiology to monitor cancer treatment. Crit Rev Oncol Hematol 58 2 (2006) 95-113
43. Atri M. New technologies and directed agents for applications of cancer imaging. J Clin Oncol 24 20 (2006) 3299-3308
44. Leach M.O., Brindle K.M., Evelhoch J.L., et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92 9 (2005) 1599-1610
45. O'Connor J.P., Jackson A., Parker G.J., and Jayson G.C. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96 2 (2007) 189-195
46. Blomley M., Claudon M., and Cosgrove D. WFUMB Safety Symposium on Ultrasound Contrast Agents: clinical applications and safety concerns. Ultrasound Med Biol 33 2 (2007) 180-186
47. Ferrara K.W., Merritt C.R., Burns P.N., Foster F.S., Mattrey R.F., and Wickline S.A. Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. Acad Radiol 7 10 (2000) 824-839
48. Lavisse S., Lejeune P., Rouffiac V., et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 43 2 (2008) 100-111
49. Hatanaka K., Kudo M., Minami Y., et al. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 51 Suppl. 1 (2008) 61-69